Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.70 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 7/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL6627427 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL12011108 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL9574618 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL12194961 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL7850301 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL2614206 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL16726317 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL66828 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL20716693 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL19270311 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617866-B2 | Humanized antibodies to mucin-16 and methods of use thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4725501-A1 | ANTIBODY SPECIFICALLY BINDING TO MASP3, AND MULTI-SPECIFIC ANTIBODY SPECIFICALLY BINDING TO MASP3 AND MASP2 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-12570728-B2 | Combinations of antibodies and bispecific antibodies comprising antigen-binding specifically recognizing Pseudomonas PcrV and Psl | Beijing Solobio Genetechnology Co., Ltd. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-20260035464-A1 | ANTIBODIES SPECIFICALLY RECOGNIZING B- AND T-LYMPHOCYTE ATTENUATOR (BTLA) AND USES THEREOF | STAIDSON BIOPHARMA INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12534521-B2 | Antibodies specifically recognizing C5A and uses thereof | STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20260015423-A1 | ANTIBODIES SPECIFICALLY RECOGNIZING PROGRAMMED CELL DEATH1 LIGAND 1 AND USES THEREOF | STAIDSON BIOPHARMA INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250361321-A1 | ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250361286-A1 | ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF | EUREKA THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12479924-B2 | Constructs specifically recognizing Glypican 3 and uses thereof | Eureka Therapeutics, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12460008-B2 | Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof | STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-11-04 | — | — | US | disclosed |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | AVICENA GROUP, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | AVICENA GROUP, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070155708-A1 | e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155708-A1 | e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella | TRUSTEES OF TUFTS COLLEGE (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1666454-A1 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TRUSTEES OF TUFTS COLLEGE (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1666453-A1 | Methods of preparing substituted tetracyclines with transition metal-based chemistries | TRUSTEES OF TUFTS COLLEGE (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1240133-B1 | METHODS OF PREPARING SUBSTITUTED TETRACYCLINES WITH TRANSITION METAL-BASED CHEMISTRIES | TUFTS COLLEGE (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-0300735-B1 | ANTIMICROBIAL PHARMACEUTICAL COMPOSITION | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1992-10-14 | — | — | EP | disclosed |
| US-4904647-A | Antimicrobial pharmaceutical composition | CHINOIN GYOGYSZER-ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1990-02-27 | — | — | US | disclosed |
| EP-0300735-A1 | Antimicrobial pharmaceutical composition | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155708-A1 | e.g. 7-(4-fluorophenyl) sancycline; for treating tetracycline responsive states; antibiotic resistance; rickettsiae: pneumococci and Salmonella | RAB7A, RPS7, SHPRH | MMP7 1877/4885MMP8 2477/4885MMP13 4278/4885 |
| US-12534521-B2 | Antibodies specifically recognizing C5A and uses thereof | C5, C5AR2, C1QBP | MMP7 4053/4885MMP8 3553/4885MMP13 4280/4885 |
| US-20260015423-A1 | ANTIBODIES SPECIFICALLY RECOGNIZING PROGRAMMED CELL DEATH1 LIGAND 1 AND USES THEREOF | PDCD1LG2, CD274, PDCD1 | MMP7 4766/4885MMP8 4082/4885MMP13 4782/4885 |
| US-12570728-B2 | Combinations of antibodies and bispecific antibodies comprising antigen-binding specifically recognizing Pseudomonas PcrV and Psl | DDX3X, MLX, HAX1 | MMP7 4856/4885MMP8 3903/4885MMP13 4287/4885 |
| US-12617866-B2 | Humanized antibodies to mucin-16 and methods of use thereof | MUC1, IGLV6-57, IGSF11 | MMP7 2365/4885MMP8 1262/4885MMP13 283/4885 |
| US-20260035464-A1 | ANTIBODIES SPECIFICALLY RECOGNIZING B- AND T-LYMPHOCYTE ATTENUATOR (BTLA) AND USES THEREOF | IGLV6-57, IGSF11, VSIG8 | MMP7 4675/4885MMP8 2795/4885MMP13 3932/4885 |
| US-20070292403-A1 | Methods of treating a neurological disorder with creatine monohydrate | CKMT1A; CKMT1B, HTT, NLN | MMP7 1205/4885MMP8 1388/4885MMP13 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.